Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Eli Lilly's late-stage trial results for its obesity pill, orforglipron, also known as Foundayo, show promise in easing sleep apnea symptoms in adults with obesity. This development is significant as it offers a potential new treatment option for a condition that affects millions of people worldwide. Sleep apnea is a serious sleep disorder that can increase the risk of cardiovascular disease, stroke, and other health complications.

The trial results suggest that orforglipron could become a game-changer in the treatment of sleep apnea, particularly for those with obesity. Current treatments for sleep apnea often involve lifestyle changes, such as weight loss, or the use of continuous positive airway pressure (CPAP) machines. However, these treatments are not always effective or well-tolerated, leaving a significant unmet need for new therapies. Lilly's plans to file for US approval by the end of the year could pave the way for a new treatment option for patients.

Industry watchers will be keeping a close eye on Lilly's regulatory filing and the potential approval of orforglipron for sleep apnea. If approved, the pill could become a major player in the obesity treatment market, which is expected to grow significantly in the coming years. Additionally, investors will be monitoring Lilly's commercialization strategy and potential market share gains. Next to watch: the FDA's review and potential approval of orforglipron, as well as Lilly's plans for launching the treatment and competing with existing players in the obesity and sleep apnea markets.

Originally reported by cnbc.com. Trade-News adds analysis for finance & markets readers.